Resistance to checkpoint blockade therapy through inactivation of antigen presentation

Treatment with immune checkpoint blockade (CPB) therapies often leads to prolonged responses in patients with metastatic melanoma, but the common mechanisms of primary and acquired resistance to these agents remain incompletely characterized and have yet to be validated in large cohorts. By analyzin...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Nat Commun
Autors principals: Sade-Feldman, Moshe, Jiao, Yunxin J., Chen, Jonathan H., Rooney, Michael S., Barzily-Rokni, Michal, Eliane, Jean-Pierre, Bjorgaard, Stacey L., Hammond, Marc R., Vitzthum, Hans, Blackmon, Shauna M., Frederick, Dennie T., Hazar-Rethinam, Mehlika, Nadres, Brandon A., Van Seventer, Emily E., Shukla, Sachet A., Yizhak, Keren, Ray, John P., Rosebrock, Daniel, Livitz, Dimitri, Adalsteinsson, Viktor, Getz, Gad, Duncan, Lyn M., Li, Bo, Corcoran, Ryan B., Lawrence, Donald P., Stemmer-Rachamimov, Anat, Boland, Genevieve M., Landau, Dan A., Flaherty, Keith T., Sullivan, Ryan J., Hacohen, Nir
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2017
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5656607/
https://ncbi.nlm.nih.gov/pubmed/29070816
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-017-01062-w
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars